Inhibitex to Present at Two Upcoming Investor Conferences

ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following two investor conferences in November:

  • The Oppenheimer 21st Annual Healthcare Conference on November 3, 2010 at 1:35 PM ET. The conference is being held at the Waldorf-Astoria in New York City.
  • Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010 at 10:00 AM ET. The conference is being held at the St. Regis Hotel in New York City.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1 clinical development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development, and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.



CONTACT:

Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
[email protected]
or
The Trout Group
Lee M. Stern, CFA, 646-378-2922
[email protected]

KEYWORDS:   United States  North America  Georgia  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Infectious Diseases  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.